DEF: Cigna Group Reports Strong 2025, Announces CEO Transition

Sentiment:

Proxy Statement 13 March 2026 4:36 PM

The Cigna Group reports robust 2025 financial results, outlines strategic advancements, and announces a planned CEO succession for July 1, 2026.

Summary

Full-year total revenues grew 11% to $275 billion in 2025.
Shareholders net income for 2025 was $6 billion, or $22.18 per share, with adjusted income from operations reaching $8 billion, or $29.84 per share.
The company generated $9.6 billion in cash flow from operations and returned $5.2 billion to shareholders through dividends and share repurchases.
Strategic portfolio shaping included a $3.5 billion investment in Shields Health Solutions and the completion of a $4.9 billion sale of Medicare Advantage and related businesses.
Launched 'Commitments to Better' initiatives focusing on easier access to care, better support, better value (rebate-free Express Scripts model), accountability (linking compensation to Net Promoter Score), and transparency (Customer Transparency Report, Clearity health plan).
CEO David M. Cordani will retire effective July 1, 2026, transitioning to Executive Chair, with Brian C. Evanko, current President and COO, becoming the new CEO.
Michael J. Hennigan joined the Board in 2025, and the Board committee structure was realigned effective January 1, 2026, with the Audit Committee becoming Audit & Compliance and the Finance Committee becoming Finance & Technology.
Shareholders will vote on director elections, executive compensation, and auditor ratification at the Annual Meeting on April 22, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid financial performance and proactive strategic adjustments in a challenging healthcare environment. The planned CEO transition and strong governance practices contribute to stability, though ongoing cost pressures and legal challenges warrant continued monitoring.

Positives

Achieved 11% year-over-year revenue growth, reaching $275 billion in 2025.
Reported strong shareholders net income of $6 billion ($22.18/share) and adjusted income from operations of $8 billion ($29.84/share) for 2025.
Generated robust cash flow from operations of $9.6 billion.
Returned $5.2 billion to shareholders through dividends and share repurchases.
Successfully executed strategic portfolio shaping with a $3.5 billion investment in Shields Health Solutions and a $4.9 billion divestiture of Medicare Advantage and related businesses to focus on higher-growth sectors.
Made tangible progress on 'Commitments to Better' initiatives, including expanding access to affordable fertility treatments and reducing prior authorizations by approximately 15% for routine services.
Introduced a new rebate-free model for Express Scripts Pharmacy Benefits, aiming to lower out-of-pocket costs for customers.
Aligned leader compensation with customer and patient satisfaction (Net Promoter Score) to enhance accountability.
Launched Clearity, a copay-only health plan leveraging AI-powered tools for transparency and personalized decision-making.
Expanded GLP-1 solutions through the Evernorth EnReachRx program and announced plans for a $0 out-of-pocket STELARA biosimilar for eligible Accredo patients, potentially saving individuals around $4,000 per year.
Enhanced behavioral health access through Evernorth Behavioral Care Group, now reaching over 5,000 providers across all 50 states.
Extended global reach by expanding presence in Oman.
Supported over 80,000 cancer patients and more than 110,000 women and families with fertility needs in 2025.
Recognized as #1 among healthcare providers and in the top 10 overall on 'America's Most JUST Companies' list by JUST Capital and CNBC.
Achieved an ACDP score, indicating a high level of environmental leadership, and a Silver medal status from EcoVadis, placing it among the top 15% of scored companies for sustainability.
Employee volunteer hours increased by approximately 30% compared to 2024, totaling nearly 114,000 hours.
CEO David Cordani's stock holdings, net of unvested restricted stock, increased 39% between year-end 2020 and 2025, demonstrating strong alignment with shareholder interests.
Executive compensation program is heavily performance-based, with approximately 92% of CEO total target pay and 82% of other NEOs' average target pay at risk.
Received strong shareholder support for the executive compensation program, with approximately 89% of votes cast in favor at the 2025 Annual Meeting.

Negatives

A federal court allowed a class-action lawsuit to proceed against the company, alleging the use of an algorithm (PxDx) to automatically deny claims without medical professional review, with the court finding 'abuse of discretion'.
Medical associations, including the California Medical Association, criticized a new company policy (Evaluation and Management Coding Accuracy) that would have automatically downgraded and reduced payment for certain medical claims, citing administrative burdens.
The company was sued for allegedly sharing patient medical information through the use of website tracking tools.
Persistent high medical costs, particularly for specialty injectable drugs and behavioral health services, are expected to continue through 2025 and 2026.
The company's stock was $340 in 2022 but only $279 in late 2025, indicating underperformance relative to a robust broader stock market.
The 2023-2025 Strategic Performance Shares (SPS) award paid out at 73% of target, with relative Total Shareholder Return (TSR) placing in the 25th to 50th percentile (54% payout) and an absolute TSR of (4.6)%.
Compensation Actually Paid for the PEO and average non-PEO NEOs decreased by 5.6% and 48.3% respectively over the 2021-2025 period, while the company's cumulative TSR grew by 44.5% and the S&P 500 Health Care Index TSR grew by 48.4%, suggesting a potential disconnect between pay and market performance.

Risks

Operating in a complex and rapidly evolving healthcare environment influenced by economic, geopolitical, legislative, and technological factors.
Facing persistent high medical costs, particularly for specialty injectable drugs and behavioral health services, which are expected to continue through 2025 and 2026.
Risks associated with strategic planning, including the selection and implementation of business plans, capital resource allocation, and the ability to adapt to changing market dynamics.
Operational risks related to business management, key business process controls, and business continuity.
Financial risks, including the ability to maintain desired debt ratings, appropriate liquidity levels, and the reliability of financial reporting.
Compliance risks with laws and regulations governing the business, as well as maintaining high ethical and business practice standards.
Cybersecurity risks and threats, requiring robust programs and strategies to mitigate evolving risks.
Risks associated with the use of Artificial Intelligence (AI) models, necessitating dedicated governance to ensure consistency with health equity and compliance with applicable laws and regulations.
Potential for shareholder actions, such as written consent proposals, to impose significant administrative and financial burdens on the company.
Exposure to litigation and regulatory matters, including a class-action lawsuit regarding claims denials and allegations of sharing patient medical information through website tracking tools.

Future Outlook

The Cigna Group is committed to a long-term perspective, focusing on investing in differentiated capabilities, customer innovations, and talented people, while continuously refining its strategy. For 2026 and beyond, the company will be guided by its 'Lead to One' strategy, placing the customer at the center and embracing bold approaches for self-disruption to drive positive change in healthcare. The company is strategically, operationally, and financially positioned for continued vision delivery and a smooth leadership transition in 2026. High medical costs, particularly for specialty injectable drugs and behavioral health services, are expected to persist through 2025 and 2026. The 2026-2028 Strategic Performance Shares program will adjust its weighting to 70% for adjusted income from operations per share and 30% for relative Total Shareholder Return. The 2025 Corporate Impact Report is expected to be published in summer 2026.

Management Comments

"Our mission—to improve the health and vitality of those we serve—guides everything we do."
"We define performance as providing value for our customers, patients, and clients. In turn, we have achieved sustainable growth for our shareholders."
"As we reflect on the past year and look ahead, our Board and management team remain committed to leading the company with a long-term perspective: investing in differentiated capabilities, customer innovations and talented people, continuously refining our strategy, and holding ourselves accountable for the outcomes we deliver."
"Adhering to the status quo in health care is unsustainable. Meeting the evolving needs of those we serve requires us to anticipate and address consumer expectations more directly, personally, and transparently."
"The momentum and strength that The Cigna Group carries into 2026 positions us strategically, operationally, and financially to deliver on our vision as we prepare to transition leadership of the company."
"Mr. Evanko has been a driving force in The Cigna Group’s focus on building a sustainable model for health care."
"We do not view AI as a replacement for expert decisions made by patients’ physicians or employees at The Cigna Group."

Industry Context

StockSavvy.ai notes that The Cigna Group's strategic divestiture of non-core Medicare Advantage businesses and concurrent investments in specialty pharmaceuticals (Shields Health Solutions) and transparent benefits (Clearity, rebate-free PBM model) align with broader industry trends. Health insurers are increasingly optimizing portfolios for higher-growth, value-based care segments and responding to consumer demands for greater transparency and affordability, particularly in pharmacy benefits and prior authorization processes. The company's emphasis on AI-powered tools for efficiency and personalized care also reflects a significant industry shift towards digital transformation. The ongoing challenge of high medical costs, especially for specialty drugs and behavioral health, is a systemic issue impacting the entire healthcare sector, underscoring the need for continued innovation in cost management and care delivery.

Comparison to Industry Standards

The Cigna Group was named #1 among healthcare providers and #10 overall on 'America's Most JUST Companies' list by JUST Capital and CNBC, indicating strong performance in business behavior compared to industry peers.
The company's CDP score increased to A-, reaching a high level of environmental leadership, suggesting it is performing well against global environmental benchmarks.
Awarded Silver medal status by EcoVadis, placing it among the top 15% of all scored companies for environment, labor and human rights, ethics, and sustainable procurement topics, demonstrating strong ESG performance relative to a broad range of companies.
The 2023-2025 Strategic Performance Shares (SPS) award's relative Total Shareholder Return (TSR) performance was in the 25th to 50th percentile of its SPS peer group, indicating average to slightly below-average performance compared to a specific set of competitors.
The company's executive compensation program historically weighted relative TSR more heavily than many peers, but is adjusting to align more with market practice by shifting SPS weighting to 70% adjusted income from operations per share and 30% relative TSR for 2026-2028.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	David M. Cordani	Brian C. Evanko	July 1, 2026	Succession planning; Mr. Cordani retiring as CEO and transitioning to Executive Chair.
Executive Chair of the Board of Directors	NA	David M. Cordani	July 1, 2026	Transition from CEO role as part of succession planning.
President and Chief Operating Officer	NA	Brian C. Evanko	March 2025	Promotion to drive customer focus and accelerate growth strategy.
Executive Vice President, Chief Financial Officer	NA	Ann M. Dennison	March 13, 2025	Promotion from Deputy CFO.
Executive Vice President, Chief Administrative Officer, and General Counsel	NA	Nicole S. Jones	2025	Role expanded to include responsibility for enterprise marketing.
Executive Vice President, Strategy and Business Development	NA	Everett Neville	2025	Assumed executive responsibility for strategy and business development.
Executive Vice President, Global Chief Information Officer	Noelle K. Eder	Durga Prasad (DP) Koka	September 2025	Ms. Eder voluntarily resigned effective May 16, 2025.
Executive Vice President, Enterprise Strategy, The Cigna Group and President and Chief Executive Officer, Evernorth Health Services	Eric P. Palmer	NA	April 26, 2025	Involuntary termination without cause.
Lead Independent Director	Eric C. Wiseman	Eric J. Foss	April 1, 2026	Part of CEO and board leadership succession planning.
Chair of the Corporate Governance Committee	Donna F. Zarcone	Eric C. Wiseman	April 1, 2026	Transition from Lead Independent Director role.
Board Member	NA	Michael J. Hennigan	2025	New appointment to leverage expertise in complex, regulated businesses.
Board Member	William J. DeLaney	NA	April 23, 2025	Retirement from the Board.
Board Member	Elder Granger, M.D.	NA	December 31, 2025	Retirement from the Board.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Leadership Structure	David M. Cordani will transition from Chair and CEO to Executive Chair of the Board, Brian C. Evanko will become CEO, Eric J. Foss will become Lead Independent Director, and Eric C. Wiseman will become Chair of the Corporate Governance Committee.	July 1, 2026 (CEO/Executive Chair), April 1, 2026 (Lead Independent Director/Corporate Governance Chair)	Designed to provide an orderly and effective transition of management responsibilities while ensuring strong leadership and independent oversight by the Board.
Committee Structure	The Compliance Committee was sunsetted as a stand-alone committee, the Audit Committee became the Audit & Compliance Committee, and the Finance Committee became the Finance & Technology Committee.	January 1, 2026	Reflects an ongoing commitment to strong corporate governance, aligning committee responsibilities with strategic priorities and providing additional opportunities for the full Board to focus on significant matters.
Committee Composition	Changes were made to the Audit & Compliance, Corporate Governance, Finance & Technology, People Resources, and Executive Committee compositions to ensure directors with necessary skills and experience, balance continuity, and expand experience.	April 1, 2026	Aims to optimize committee effectiveness and oversight in light of new mandates and leadership changes.
Shareholder Right to Call Special Meeting	By-Laws permit shareholders holding 25% or more of outstanding common stock, held continuously for at least one year, to call a special meeting. This was implemented in response to shareholder feedback.	Post-2019 shareholder outreach	Enhances shareholder rights and accountability, providing a mechanism for shareholders to raise important matters with procedural protections.
Proxy Access Right	Adopted a proxy access by-law allowing a shareholder or group of up to 20 shareholders owning in aggregate three percent or more of outstanding common stock continuously for at least three years to nominate and include in proxy materials director nominees constituting up to 20% of the number of directors in office or two nominees, whichever is greater.	2017	Strengthens shareholder influence on board composition and accountability.
Voting Standard	All directors are elected annually by a majority vote standard for uncontested elections.	Since the 2018 Annual Meeting	Increases director accountability to shareholders.
Supermajority Voting Provisions	Removed all supermajority voting provisions in governing documents, allowing charter and by-law amendments by the affirmative vote of a majority of the company's outstanding stock.	2018	Simplifies shareholder ability to effect changes and reduces barriers to corporate action.
Poison Pill	The Cigna Group does not have a shareholder rights plan (poison pill) in place.	NA	Indicates a commitment to shareholder-friendly governance and avoids anti-takeover defenses.
Clawback Policy	Adopted a standalone clawback policy compliant with the Dodd-Frank Act, Rule 10D-1 of the Exchange Act, and NYSE Rule 303A.14, in addition to pre-existing policy. This allows recoupment of incentive-based compensation in case of restatement due to error or intentional misconduct, and for breaches of restrictive covenants.	October 2023	Strengthens accountability for executive officers and discourages misconduct.
Equity Grant Policy	All grants of company securities to employees and consultants under equity compensation plans are made on specific Grant Dates (March 1, June 1, September 1, December 1), or the preceding business day if not a business day. Grants of option-like features are not timed with material non-public information release.	March 2024	Enhances transparency and reduces potential for insider trading concerns related to equity awards.
Hedging and Pledging Restrictions	The Insider Trading Policy prohibits directors, executive officers, and all other employees from engaging in hedging or pledging transactions (e.g., put/call options, short sales, zero cost collars, forward sale contracts).	NA	Aligns executive and employee interests with long-term shareholder value by preventing risk-mitigating strategies that could decouple their interests from stock performance.

Legal Proceedings

A federal court allowed a class-action lawsuit to proceed against the company, charging that it used an algorithm (PxDx) to automatically deny claims without review by a medical professional, with the court finding an 'abuse of discretion'.
The company was sued for allegedly sharing patient medical information through the use of website tracking tools.
Nicole S. Jones, Executive Vice President, Chief Administrative Officer, and General Counsel, provides oversight of key regulatory inquiries and litigation.

Related Party Transactions

There were no related-person transactions in 2025 requiring disclosure under SEC rules.

Stakeholder Impact

Shareholders: Benefited from strong financial results, $5.2 billion returned through dividends and share repurchases, and strategic portfolio adjustments aimed at long-term growth. However, the stock's underperformance relative to the broader market and peer group over recent years, along with ongoing legal challenges, could be areas of concern.
Customers/Patients: Positively impacted by 'Commitments to Better' initiatives, including easier access to care, better support, and better value (e.g., rebate-free PBM, Clearity health plan, reduced prior authorizations, GLP-1 solutions, fertility treatment access). However, trust and satisfaction could be negatively affected by the class-action lawsuit regarding the PxDx algorithm and concerns about sharing patient medical information.
Employees: Benefited from significant investment in health and vitality (~20% of payroll in the US), fair and market-competitive compensation, robust growth and development programs (average 45 hours of learning), a low voluntary turnover rate (~9%), and strong pay equity (female and underrepresented groups earning >99 cents for every dollar). Employee engagement is a strategic priority.
Providers: Efforts to streamline and reduce prior authorization processes (with a goal of 80% real-time authorizations) aim to improve interactions. However, past policies like 'Evaluation and Management Coding Accuracy' were criticized for creating administrative burdens and reducing payments.
Clients: Benefited from the new rebate-free pharmacy benefit model designed to lower costs and improve transparency. Long-term renewals and extensions with major clients ensure stability and continued partnership.
Communities: Positively impacted by approximately $52.2 million in combined giving, 114,000 employee volunteer hours, and multi-year initiatives focused on youth mental health, veteran housing, and reducing health equity barriers. Disaster relief support was also provided.
Creditors: Supported by strong financial performance, robust cash flow, and the maintenance of an investment-grade profile, which enhances creditworthiness.

Next Steps

Shareholders are invited to attend and vote at the 2026 Annual Meeting on April 22, 2026.
Shareholders will vote on the election of twelve director nominees for one-year terms.
Shareholders will provide advisory approval of executive compensation.
Shareholders will vote on the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026.
Shareholders will consider a shareholder proposal regarding the right to act by written consent.
Brian C. Evanko will become CEO effective July 1, 2026.
David M. Cordani will transition to Executive Chair effective July 1, 2026.
Eric Foss will become Lead Independent Director effective April 1, 2026.
Eric Wiseman will transition to Chair of the Corporate Governance Committee effective April 1, 2026.
The 2025 Corporate Impact Report is expected to be published in summer 2026.
The Board and management will continue driving positive change in healthcare through the 'Lead to One' strategy.
The next vote on the frequency of say-on-pay advisory votes will be held at the 2029 Annual Meeting.

Key Dates

Date	Description
2004-12-31	Cigna Supplemental Pension Plan frozen.
2009-07-01	Cigna Pension Plan and Cigna Supplemental Pension Plan of 2005 frozen.
2017	Proxy access by-law adopted.
2018	All directors began to be elected annually; supermajority voting provisions removed from governing documents.
2019	Shareholder proposal to permit written consent received majority support.
2020-01-01	Future deferrals to Express Scripts Deferred Compensation Plan frozen.
2021	Shareholder proposal for written consent rejected.
2022-01	David Cordani appointed Chair of the Board; Eric Wiseman became Lead Independent Director.
2024-03	Equity Grant Policy adopted.
2025-03	Brian C. Evanko promoted to President and Chief Operating Officer.
2025-03-13	Ann M. Dennison appointed Executive Vice President, Chief Financial Officer.
2025-04	Eric P. Palmer departed the company.
2025-04-23	William J. DeLaney retired from the Board.
2025-05-16	Noelle K. Eder voluntarily resigned.
2025-06-02	Michael J. Hennigan joined the Board.
2025-09	Durga Prasad (DP) Koka appointed Executive Vice President and Global Chief Information Officer.
2025-10	Board approved changes to the committee structure.
2025-12-31	Fiscal year end; Elder Granger, M.D. retired from the Compliance Committee and Audit Committee.
2026-01-01	Committee structure changes became effective (Audit & Compliance Committee, Finance & Technology Committee).
2026-02-23	Record date for the Annual Meeting of Shareholders.
2026-02-25	Board approved compensation arrangements for Brian C. Evanko (as CEO) and David M. Cordani (as Executive Chair).
2026-02-27	Date the 2023-2025 Strategic Performance Shares (SPS) award was paid out.
2026-03-01	First installment vesting for 2025 restricted stock and stock options.
2026-03-13	Proxy Statement distributed or made available.
2026-04-01	Brian C. Evanko becomes a Board member; Eric J. Foss becomes Lead Independent Director; Eric C. Wiseman transitions to Chair of the Corporate Governance Committee.
2026-04-16	Deadline for 401(k) voting instructions (11:59 p.m. Eastern Time).
2026-04-17	Deadline to submit questions in advance of the Annual Meeting.
2026-04-21	Deadline for internet/telephone voting for record holders (11:59 p.m. Eastern Time).
2026-04-22	Annual Meeting of Shareholders (11:00 a.m. Eastern Time, virtual).
2026-07-01	Brian C. Evanko becomes CEO; David M. Cordani becomes Executive Chair.
2026-07	Neesha Hathi assumes expanded role of Managing Director, Head of Wealth Advisory, Banking and Trust Services at Charles Schwab.
2026-08	Expected publication of the 2025 Corporate Impact Report.
2026-11-13	Deadline for shareholder proposals to be included in the 2027 proxy statement (pursuant to SEC Rule 14a-8).
2026-12-23	Earliest date for non-Rule 14a-8 shareholder proposals for the 2027 Annual Meeting.
2027-01-22	Latest date for non-Rule 14a-8 shareholder proposals for the 2027 Annual Meeting.
2029	Next vote on the frequency of say-on-pay advisory votes.

Recommendation

hold

The Cigna Group demonstrates solid financial performance and a clear strategic direction with its 'Commitments to Better' and portfolio optimization. The planned CEO succession appears well-managed, ensuring leadership continuity. However, the stock's underperformance relative to the broader market and peer group over recent years, coupled with ongoing legal and regulatory challenges related to claims denials and data privacy, suggests a 'hold' recommendation. While the company is addressing key industry issues like affordability and access, these headwinds warrant caution for new investment, while existing shareholders should monitor the execution of strategic initiatives and resolution of legal matters.

Keywords

Healthcare, Health Insurance, Pharmacy Benefits, PBM, Cigna, Evernorth, Express Scripts, Proxy Statement, Corporate Governance, Executive Compensation, Financial Results, Strategic Planning, Risk Management, AI in Healthcare, Shareholder Meeting, CEO Succession, Dividends, Share Repurchases, ESG, Sustainability, Prior Authorization, Specialty Pharmacy

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.